Patents by Inventor Tatsuya Moutai

Tatsuya Moutai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11578132
    Abstract: It is an object of the present invention to provide a method for efficiently producing a B cell population comprising B cells that recognize a specific antigen. According to the present invention, provided is a method for producing a B cell population, comprising: a step (c) of culturing a cell population comprising B cells together with a specific antigen in the absence of IL-21, in the absence of IL-4, and in the presence of a cytokine other than IL-21 and IL-4, while giving stimulation mediated by CD40 and a BAFF receptor to the cells; and a step (d) of culturing the cell population comprising B cells, while giving stimulation mediated by has to the cells, so as to obtain a B cell population comprising B cells that recognize the specific antigen.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: February 14, 2023
    Assignees: KANEKA CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Tatsuya Moutai, Tomoyuki Nakaishi, Hiroshi Kita, Mitsuaki Kitano, Daisuke Kitamura
  • Publication number: 20220162259
    Abstract: A peptide complex including: a peptide; and a cell-membrane-permeability-imparting group introduced into the peptide, wherein the cell-membrane-permeability-imparting group includes a dendritic structure including four or more branches, and at least four branches of the four or more branches include basic functional groups at ends thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: May 26, 2022
    Applicant: KANEKA CORPORATION
    Inventors: Keishi TAKATSU, Toshihiro SHIKAKURA, Yuka MATSUDA, Tatsuya MOUTAI, Hirofumi MAEDA, Hiroshi KITA, Mitsuaki KITANO
  • Publication number: 20220048953
    Abstract: Novel cell-penetrating peptides are provided, which are excellent in cell membrane permeability. The cell-penetrating peptide or salt thereof according to the present invention is characterized in comprising the sequence represented by formula (I) or the formula (II) as follows: X-(A-B-C)l-(D)m-(Arg)n (Formula I) or X-(Arg)n-(D)m-(A-B-C)l (Formula II), wherein X is a physiologically active peptide, A, B and C are aliphatic amino acids, D is an arbitrary amino acid, l is an integer of 1 or more and 4 or less, m is an integer of 0 or more and 5 or less, when l is 1, n is an integer of 8 or more, when l is 2, n is an integer of 6 or more, when l is 3, n is an integer of 4 or more, when l is 4, n is an integer of 4 or more.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 17, 2022
    Applicant: KANEKA CORPORATION
    Inventors: Yuka MATSUDA, Hiroshi KITA, Keishi TAKATSU, Tatsuya MOUTAI, Mitsuaki KITANO
  • Patent number: 11155833
    Abstract: A method for producing a transgenic cell, may include contacting, in vitro, (i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with (ii) a target cell and an antibody specific to the target cell, and/or a target cell comprising a membrane antibody, to infect the target cell with the virus.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: October 26, 2021
    Assignee: KANEKA CORPORATION
    Inventors: Tomoyuki Nakaishi, Tatsuya Moutai, Hiroshi Kita, Mitsuaki Kitano
  • Publication number: 20200071410
    Abstract: It is an object of the present invention to provide a method for efficiently producing a B cell population comprising B cells that recognize a specific antigen. According to the present invention, provided is a method for producing a B cell population, comprising: a step (c) of culturing a cell population comprising B cells together with a specific antigen in the absence of IL-21, in the absence of IL-4, and in the presence of a cytokine other than IL-21 and IL-4, while giving stimulation mediated by CD40 and a BAFF receptor to the cells; and a step (d) of culturing the cell population comprising B cells, while giving stimulation mediated by has to the cells, so as to obtain a B cell population comprising B cells that recognize the specific antigen.
    Type: Application
    Filed: January 15, 2018
    Publication date: March 5, 2020
    Applicants: KANEKA CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Tatsuya Moutai, Tomoyuki Nakaishi, Hiroshi Kita, Mitsuaki Kitano, Daisuke Kitamura
  • Publication number: 20190271006
    Abstract: A method for producing a transgenic cell, may include contacting, in vitro, (i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with (ii) a target cell and an antibody specific to the target cell, and/or a target cell comprising a membrane antibody, to infect the target cell with the virus.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 5, 2019
    Applicant: KANEKA CORPORATION
    Inventors: Tomoyuki Nakaishi, Tatsuya Moutai, Hiroshi Kita, Mitsuaki Kitano